Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / Tarsus Pharmaceuticals, Inc.

M&Acompleted an acquisition (SEC 8-K)10 Sept 2026

Tarsus Pharmaceuticals, Inc.

10 Sept 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
10 Sept 2026
Ticker
TARS
Role
Completed an acquisition
Sector
Pharma and biotech
Sic
2836
Items
2.01, 8.01, 9.01
Summary
On September 4, 2026 (the "Closing Date"), Tarsus Pharmaceuticals, Inc. (the "Company") completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a Delaware corporation ("Alkeus"), pursuant to that certain Agreement and Plan of Merger, dated as of July 31, 2026 (the "Merger Agreement"), by and amo
Location
Irvine, CA
State
California
Country
United States
SEC CIK
1819790
Reference
0001819790-26-000066
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at Tarsus Pharmaceuticals, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

Across AOS Research

Other records for Tarsus Pharmaceuticals, Inc. in our registers.

More in Completed an acquisition

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.